OAC
SLNO

OMERS Administration Corp’s Soleno Therapeutics SLNO Stock Holding History

OMERS Administration Corp’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,200
Closed -$253K – 1069
2024
Q2 		$253K Buy
+6,200
New +$263K ﹤0.01% 843

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OMERS Administration Corp's SLNO Position: Q3 2024 in Review

OMERS Administration Corp sold out of Soleno Therapeutics (SLNO) in Q3 2024, closing a stake of 6,200 shares — an estimated $253K sold.

OMERS Administration Corp first reported a position in SLNO in Q2 2024 and held it in 1 quarter. The position peaked at $253K in Q2 2024. 142 funds tracked by Wall St. Rank hold SLNO as of Q3 2024.

  • OMERS Administration Corp reported no remaining Soleno Therapeutics position as of Q3 2024 after selling out during the quarter.
  • OMERS Administration Corp sold 6,200 Soleno Therapeutics shares in Q3 2024, an estimated $253K.
  • OMERS Administration Corp first reported a position in Soleno Therapeutics in Q2 2024 and held it in 1 quarter.
  • OMERS Administration Corp's Soleno Therapeutics position peaked at $253K in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2024.

Based on OMERS Administration Corp's 13F filing for Q3 2024, filed 13 Nov 2024.